Analysts Predict 23% Gains Ahead For PBE
March 23, 2018 at 10:18 AM EDT
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the PowerShares Dynamic Biotechnology & Genome Portfolio ETF (PBE), we found that the implied analyst target price for the ETF based upon its underlying holdings is $62.17 per unit.